三阴性乳腺癌各亚型精准医疗策略研究进展

doi:10.11904/j.issn.1002-3070.2021.06.008

摘要/Abstract

摘要： 三阴性乳腺癌(Triple negative breast cancer,TNBC)约占乳腺癌总数的15%,缺乏明确的靶向治疗及内分泌治疗靶点,治疗手段相对单一,且复发较早,总生存率较差。早期TNBC的主要治疗方法是新辅助化疗和确定性手术,TNBC分子分型的提出使得TNBC个体化治疗进入精准治疗时代。基于TNBC各亚型特点进行精准医疗策略,可使患者获得临床获益,本文旨在对TNBC各亚型的精准医疗策略研究进展及精准医疗临床获益进行综述。

关键词: 三阴性乳腺癌, 免疫, 精准医学

Abstract: Triple negative breast cancer(TNBC)accounts for about 15% of the total number of breast cancer.There is no clear target for targeted therapy and endocrine therapy.The treatment method is relatively single,and the recurrence is early.The overall survival rate is poor.The main treatment methods of early TNBC are neoadjuvant chemotherapy and definitive surgery.The proposal of TNBC molecular typing makes the individualized treatment of TNBC enter the era of precision treatment.Precision medicine strategy based on the characteristics of TNBC subtypes can make patients get clinical benefits.This paper aims to review the research progress and clinical benefits of precision medicine strategy of TNBC subtypes.

Key words: Triple negative breast cancer, Immunology, Precision medicine

中图分类号:

R737.9

史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.

SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer[J]. Journal of Practical Oncology, 2021, 35(6): 529-533.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/529

参考文献

1 Antonio M,Giulia V,Giuseppe C.Recent advances in triple negative breast cancer:the immunotherapy era[J].BMC Med,2019,17(1):90-102.
2 González MS,Pérez MB,Carretero BI,et al.Molecular features of metaplastic breast carcinoma:an infrequent subtype of triple negative breast carcinoma[J].Cancers Basel,2020,12(7):1832-1841.
3 Jiang YZ,Ma D,Suo C,et al.Genomic and transcriptomic landscape of triple negative breast cancer:subtypes and treatment strategies[J].Cancer Cell,2019,35(3):428-440.
4 Zhao S,Ma D,Xiao Y,et al.Molecular subtyping of triple negative breast cancers by Immunohistochemistry:molecular basis and clinical relevance[J].Oncologist,2020,25(10):1481-1491.
5 Jin SL,Susan EY,Yuan Y.Neoadjuvant treatment for triple negative breast cancers:recent progresses and challenges[J].Cancers Basel,2020,12(6):1404-1414.
6 Chen L,Yang L,Yao L,et al.Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients[J].Nat Commun,2018,9(1):1357-1365.
7 O′Leary B,Finn RS,Turner NC.Treating cancer with selective CDK4/6 inhibitors[J].Nat Rev Clin Oncol,2016,13(7):417-430.
8 Astvatsaturyan K,Yue Y,Walts AE,et al.Androgen receptor positive triple negative breast cancer:clinicopathologic,prognostic and predictive features[J].PLoS One,2018,13(6):e0197827.
9 Traina TA,Miller K,Yardley DA,et al.Enzalutamide for the treatment of androgen receptor expressing triple negative breast cancers[J].Clin Oncol,2018,36(9):884-890.
10 Fu LL,Tian M,Li X,et al.Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery[J].Oncotarget,2015,6(8):5501-5516.
11 Park IH,Yang HN,Jeon SY,et al.Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple negative breast cancer[J].Sci Rep,2019,9(1):13305-13318.
12 Gul A,Leyland JB,Dey N.A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor positive breast cancer:a genomic algorithm-based treatment approach[J].Am J Cancer Res,2018,8(12):2359-2376.
13 Fassl A,Brain C,Abu RM,et al.Single cell dynamics determines response to CDK4/6 Inhibition in triple negative breast cancers[J].Clin Cancer Res,2017,23(18):5561-5572.
14 Telli ML,Timms KM,Reid J,et al.Homologous recombination deficiency(HRD)Score predicts response to platinum containing neoadjuvant chemotherapy in patients with triple negative breast cancers[J].Clin Cancer Res,2016,22(15):3764-3773.
15 Von MG,Schneeweiss A,Loibl S,et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer(GeparSixto;GBG 66):a randomised phase 2 trial[J].Lancet Oncol,2014,15(7):747-756.
16 Xia LY,Hu QL,Zhang J,et al.Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer:a meta-analysis of 36480 cases[J].World J Surg Oncol,2020,18(1):129-140.
17 Sikov WM,Berry DA,Perou CM,et al.Impact of the addition of carboplatin and/or bevacizu- mab to neoadjuvant once per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer:CALGB 40603(Alliance)[J].J Clin Oncol,2015,33(1):13-21.
18 Gluz O,Nitz U,Liedtke C,et al.Comparison of neoadjuvant nab+paclitaxel+carboplatin vs nab+paclitaxel+gemcitabine in triple-negative breast cancer:randomized WSG-ADAPT-TN trial results[J].J Natl Cancer Inst,2018,110(6):628-637.
19 Toss A,Molinaro E,Venturelli M,et al.BRCA detection rate in an Italian cohort of luminal early-onset and triple negative breast cancer patients without family history:when biology overcomes genealogy[J].Cancers Basel,2020,12(5):1497-1508.
20 Wang N,Li K,Huang WF,et al.BRCA efficacy of platinum in advanced triple negative breast cancer with germline mutation determined by next generation sequencing[J].Chin J Cancer Res,2020,32(2):149-162.
21 Tutt A,Tovey H,Cheang MCU,et al.Carboplatin in BRCA1/2-mutated and triple negative breast cancers BRCAness subgroups:the TNT trial[J].Nat Med,2018,24(5):628-637.
22 Chen X,Wang J,Fu Z et al.Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression[J].Sci Rep,2017,7(1):17724-17741.
23 Chopra N,Tovey H,Pearson A,et al.Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancers[J].Nat Commun,2020,11(1):2662-2681.
24 Robson M,Im SA,Senkus E,et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J].N Engl J Med,2017,377(17):523-533.
25 Ettl J,Quek RGW,Lee KH,et al.Quality of life with talazoparib versus physician′s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation:patient-reported outcomes from the EMBRACA phase III trial[J].Ann Oncol,2018,29(9):1939-1947.
26 Schmid P,Adams S,Rugo HS,et al.Atezolizumab and nab-paclitaxel in advanced triple negative breast cancer[J].N Engl J Med,2018,379(22):2108-2121.
27 Nanda R,Liu MC,Yau C,et al.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer:an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial[J].JAMA Oncol,2020,6(5):1-9.
28 Loibl S,Untch M,Burchardi N,et al.A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer:clinical results and biomarker analysis of GeparNuevo study[J].Ann Oncol,2019,30(8):1279-1288.
29 Balko JM,Schwarz LJ,Luo N,et al.Triple negative breast cancer with amplification of JAK2 at the 9p24 locus demonstrate JAK2 specific dependence[J].Sci Transl Med,2016,8(334):334-353.
30 Pascual J,Turner NC.Targeting the PI3-kinase pathway in triple negative breast cancers[J].Ann Oncol,2019,30(7):1051-1060.
31 Kim SB,Dent R,Im SA,et al.Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer(LOTUS):a multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet Oncol,2017,18(10):1360-1372.
32 Schmid P,Abraham J,Chan S,et al.Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple negative breast cancer:the PAKT trial[J].J Clin Oncol,2020,38(5):423-433.
33 Gerber B,Loibl S,Eidtmann H,et al.Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple negative breast cancer;results from the geparquinto study(GBG 44)[J].Ann Oncol,2013,24(12):2978-2984.

[1]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.
[2]	陈奕心, 孙轶华, 程洋洋, 何凯桐, 郭婷. 术前炎症相关指标与可切除胃癌患者预后的相关性[J]. 实用肿瘤学杂志, 2021, 35(6): 517-522.
[3]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[4]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[5]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[6]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[7]	王哲, 祝率, 刘欢, 付蔷, 胡腾龙. SRPX2和Rab31在口腔鳞癌组织中的表达、相关性及临床意义[J]. 实用肿瘤学杂志, 2021, 35(5): 414-419.
[8]	卢俊蓉, 王惠文, 何东风. SALL4高表达在食管鳞癌临床病理及预后判定中的意义[J]. 实用肿瘤学杂志, 2021, 35(5): 420-425.
[9]	隆园辉, 陈雪松. 心理应激对肿瘤微环境中免疫细胞影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 436-440.
[10]	张伟明, 孙坚萍, 赵艳. 共刺激受体:肿瘤免疫疗法的潜在靶点[J]. 实用肿瘤学杂志, 2021, 35(5): 441-446.
[11]	金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.
[12]	吴长帅, 张宝慧, 高正莲, 张校望, 王坤. 丙泊酚抗肿瘤作用及分子机制在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 480-484.
[13]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[14]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[15]	王明明, 陈晓品. 抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 179-183.